ArticleMedicine2026
The identification of biomarkers for response to omalizumab in adult asthma based on untargeted metabolomic analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
There is a paucity of research on biomarkers that can accurately identify patients who are likely to derive benefit from anti-IgE therapy. The present study aimed to identify metabolites associated with the therapeutic response to omalizumab in adult with asthma. We performed global metabolomic profiling of plasma samples obtained from 44 patients with severe asthma prior to initiating omalizumab treatment, employing untargeted metabolomic analysis. Patients were divided into responders or non-responders based on their treatment outcomes. Between-group difference analysis and enrichment analysis were conducted to identify metabolites associated with treatment response. Compared with non-responders, responders exhibited significant up-regulated of 19 metabolites, and down-regulated of 3 metabolites in their plasma. These metabolites may serve as potential indicators for determining which severe asthma patients are likely to benefit from omalizumab. This study highlights the close relationship between the plasma metabolic profile of severe asthma patients and their response to omalizumab. It presents a promising approach for identifying patients who are most likely to benefit from this therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.